Last reviewed · How we verify
Rivastigmine Transdermal Product
At a glance
| Generic name | Rivastigmine Transdermal Product |
|---|---|
| Sponsor | UMC Utrecht |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine (PHASE4)
- Telerehabilitation Alzheimer's Disease Feasibility (TADF) (NA)
- Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium (PHASE1, PHASE2)
- Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivastigmine Transdermal Product CI brief — competitive landscape report
- Rivastigmine Transdermal Product updates RSS · CI watch RSS
- UMC Utrecht portfolio CI